{"id":3171,"date":"2015-05-05T10:17:38","date_gmt":"2015-05-05T02:17:38","guid":{"rendered":"http:\/\/wp.kmu.edu.tw\/rd\/?p=3171"},"modified":"2015-05-05T11:24:51","modified_gmt":"2015-05-05T03:24:51","slug":"%e7%a0%94%e7%a9%b6%e8%ab%96%e6%96%87%e5%88%86%e4%ba%ab-6","status":"publish","type":"post","link":"https:\/\/wp.kmu.edu.tw\/rd\/archives\/3171","title":{"rendered":"\u7814\u7a76\u8ad6\u6587\u5206\u4eab"},"content":{"rendered":"<p style=\"text-align: right\"><a href=\"http:\/\/wp.kmu.edu.tw\/rd\/archives\/3167\">\u56de\u7b2c0032\u671f\u4e3b\u9801<\/a><\/p>\n<h1><span style=\"font-size: x-large;color: #c10000\">\u4e00\u3001\u8ad6\u6587\u5206\u4eab<\/span><\/h1>\n<p><a name=\"PaperRes1\"><\/a><\/p>\n<ul>\n<li><span style=\"color: #3366ff\">\u984c\u76ee\uff1a<strong><br \/>\nAssociation of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection<br \/>\n<\/strong><\/span><\/li>\n<li>\u4f5c\u8005\uff1aHuang CF, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, Liang PC, Lin YH, Hsieh MY, Yang HL, Huang JF, Lin ZY, Chen SC, Yu ML, Chuang WL J Hepatol. 2015 Mar;62(3):512-8. doi: 10.1016\/j.jhep.2014.10.011. Epub 2014 Oct 20.\n<\/li>\n<\/ul>\n<ul>\n<li>\u6458\u8981\uff1a<br \/>\nBACKGROUND &amp; AIMS:<br \/>\nGenetic variants of patatin-like phospholipase domain-containing 3 (PNPLA3) and diabetes are associated with liver disease severity, in patients with chronic hepatitis C (CHC) infection. We aimed at exploring their interaction in determining hepatitis C virus (HCV)-related liver fibrosis.<br \/>\nMETHODS:<br \/>\nThe PNPLA3 genetic polymorphism at rs738409 was verified in 1077 biopsy-proven CHC patients. Other clinical variables, including diabetes status, were analysed for factors associated with bridging fibrosis.<br \/>\nRESULTS:<br \/>\nPatients with advanced liver fibrosis had higher proportions of the GG genotype (14.5% vs. 10.4%, p=0.06 in recessive model) and GG\/GC genotype carriage (64.0% vs. 56.8%, p=0.03 in dominant model). Stepwise logistic regression analysis revealed that factors predictive of advanced liver fibrosis included age (odds ratio [OR]: 1.02, 95% confidence intervals [CI]: 1.008-1.037, p=0.002), diabetes (OR: 1.81, CI: 1.236-2.653, p=0.002), \u03b1-fetoprotein (OR: 1.006, CI: 1.001-1.01, p=0.01), platelet counts (OR: 1.009, CI: 1.006-1.012, p&lt;0.001), and PNPLA3 rs738409 CG\/GG genotype (OR: 1.34, CI: 1.006-1.785, p=0.046). When patients were grouped according to their diabetes status, the PNPLA3 genetic variants were associated with advanced liver fibrosis in diabetic patients only, but not in non-diabetic patients. The PNPLA3 gene was the most important predictive factor of bridging fibrosis in diabetic patients, using the recessive model (OR: 4.53, CI: 1.356-15.106, p=0.014) or the dominant model (OR: 2.20, CI: 1.026-4.734, p=0.04). Compared to non-diabetic patients, patients with the diabetes\/GG genotype were more likely to have advanced liver fibrosis (OR: 8.79, CI: 2.889-26.719, p&lt;0.001), followed by those with diabetes\/non-GG genotype (OR: 1.55, CI: 1.048-2.286, p=0.03).<br \/>\nCONCLUSIONS:<br \/>\nThe effect of PNPLA3 genetic variants in HCV-related advanced liver fibrosis was enhanced in diabetic patients. The strong genetic-environmental interaction contributed to the high risk of advanced liver disease in CHC patients.<\/p>\n<\/li>\n<\/ul>\n<p><a name=\"PaperRes2\"><\/a><\/p>\n<ul>\n<li><span style=\"color: #3366ff\">\u984c\u76ee\uff1a<strong><br \/>\nSaikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry<br \/>\n<\/strong><\/span><\/li>\n<\/ul>\n<ul>\n<li>\u4f5c\u8005\uff1aLin LT, Chung CY, Hsu WC, Chang SP, Hung TC, Shields J, Russell RS, Lin CC, Li CF, Yen MH, Tyrrell DL, Lin CC, Richardson CD J Hepatol. 2015 Mar;62(3):541-8. doi: 10.1016\/j.jhep.2014.10.040. Epub 2014 Nov 4\n<\/li>\n<\/ul>\n<ul>\n<li>\u6458\u8981\uff1a<br \/>\nBACKGROUND &amp; AIMS:<br \/>\nA vaccine against hepatitis C virus (HCV) is unavailable and cost-effective antivirals that prevent HCV infection and re-infection, such as in the transplant setting, do not exist. In a search for novel and economical prophylactic agents, we examined the antiviral activity of saikosaponins (SSa, SSb2, SSc, and SSd) from Bupleurum kaoi root (BK) as entry inhibitors against HCV infection.<\/p>\n<p>METHODS:<br \/>\nInfectious HCV culture systems were used to examine the effect of saikosaponins on the complete virus life cycle (entry, RNA replication\/translation, and particle production). Antiviral activity against various HCV genotypes, clinical isolates, and infection of primary human hepatocytes were also evaluated.<\/p>\n<p>RESULTS:<br \/>\nBK and the saikosaponins potently inhibited HCV infection at non-cytotoxic concentrations. These natural agents targeted early steps of the viral life cycle, while leaving replication\/translation, egress, and spread relatively unaffected. In particular, we identified SSb2 as an efficient inhibitor of early HCV entry, including neutralization of virus particles, preventing viral attachment, and inhibiting viral entry\/fusion. Binding analysis, using soluble viral glycoproteins, demonstrated that SSb2 acted on HCV E2. Moreover, SSb2 inhibited infection by several genotypic strains and prevented binding of serum-derived HCV onto hepatoma cells. Finally, treatment with the compound blocked HCV infection of primary human hepatocytes.<\/p>\n<p>CONCLUSIONS:<br \/>\nDue to its potency, SSb2 may be of value for development as an antagonist of HCV entry and could be explored as prophylactic treatment during the course of liver transplantation.<\/p>\n<p>.<\/li>\n<\/ul>\n<p style=\"text-align: right\"><a href=\"http:\/\/wp.kmu.edu.tw\/rd\/archives\/3167\">\u56de\u7b2c0032\u671f\u4e3b\u9801<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u56de\u7b2c0032\u671f\u4e3b\u9801 \u4e00\u3001\u8ad6\u6587\u5206\u4eab \u984c\u76ee\uff1a Association of diab &hellip; <a href=\"https:\/\/wp.kmu.edu.tw\/rd\/archives\/3171\">\u95b1\u8b80\u5168\u6587 <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[40],"tags":[],"class_list":["post-3171","post","type-post","status-publish","format-standard","hentry","category-40"],"_links":{"self":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts\/3171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/comments?post=3171"}],"version-history":[{"count":1,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts\/3171\/revisions"}],"predecessor-version":[{"id":3172,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/posts\/3171\/revisions\/3172"}],"wp:attachment":[{"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/media?parent=3171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/categories?post=3171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wp.kmu.edu.tw\/rd\/wp-json\/wp\/v2\/tags?post=3171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}